Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with leukaemia driven by BCR-ABL1 (ref. 1) and other oncogenic tyrosine kinases 2,3 . Recent efforts have focused on developing more potent TKIs that also inhibit mutant tyrosine kinases 4,5 . However, even effective TKIs typically fail to eradicate leukaemia-initiating cells (LICs) 6-8 , which often cause recurrence of leukaemia after initially successful treatment. Here we report the discovery of a novel mechanism of drug resistance, which is based on protective feedback signalling of leukaemia cells in response to treatment with TKI. We identify BCL6 as a central component of this drugresistance pathway and demonstrate that targeted inhibition of BCL6 leads to eradication of drug-resistant and leukaemia-initiating subclones.
BCL6 is a known proto-oncogene that is often translocated in diffuse large B-cell lymphoma (DLBCL) 9 . In response to TKI treatment, BCR-ABL1 acute lymphoblastic leukaemia (ALL) cells upregulate BCL6 protein levels by approximately 90-fold: that is, to similar levels as in DLBCL (Fig. 1a ). Upregulation of BCL6 in response to TKI treatment represents a novel defence mechanism, which enables leukaemia cells to survive TKI treatment: Previous work suggested that TKI-mediated cell death is largely p53 independent. Here we demonstrate that BCL6 upregulation upon TKI treatment leads to transcriptional inactivation of the p53 pathway. BCL6-deficient leukaemia cells fail to inactivate p53 and are particularly sensitive to TKI treatment. BCL6 2/2 leukaemia cells are poised to undergo cellular senescence and fail to initiate leukaemia in serial transplant recipients. A combination of TKI treatment and a novel BCL6 peptide inhibitor markedly increased survival of NOD/SCID mice xenografted with patient-derived BCR-ABL1 ALL cells. We propose that dual targeting of oncogenic tyrosine kinases and BCL6-dependent feedback ( Supplementary Fig. 1 ) represents a novel strategy to eradicate drug-resistant and leukaemia-initiating subclones in tyrosine-kinase-driven leukaemia.
To elucidate mechanisms of TKI resistance in tyrosine-kinasedriven leukaemia, we performed a gene expression analysis including our and published data of TKI-treated leukaemia. We identified BCL6 as a top-ranking gene in a set of recurrent gene expression changes, some of which are shared with mitogen-activated protein-kinase kinase (MEK) inhibition in BRAF V600E mutant solid tumour cells 10 ( Supplementary Figs 2 and 3) . TKI-induced upregulation of BCL6 messenger RNA (mRNA) levels was confirmed in multiple leukaemia subtypes carrying oncogenic tyrosine kinases ( Supplementary Fig. 2) . The BCR-ABL1 kinase, encoded by the Philadelphia chromosome (Ph), represents the most frequent genetic lesion in adult ALL, defines the subtype with a particularly poor prognosis 1,4,5 and was therefore chosen as focus for this study.
To elucidate the regulation of BCL6 in Ph 1 ALL, we investigated the JAK2/STAT5 (ref. 11) and PI3K/AKT 12 pathways downstream of BCR-ABL1. We and others have shown that STAT5 suppresses BCL6 in B cells [13] [14] [15] . TKI-mediated upregulation of BCL6 was diminished by constitutively active STAT5 ( Fig. 1b ) and deletion of STAT5 was sufficient to upregulate BCL6, even in the absence of TKI treatment (Fig. 1c ). In agreement with previous work 15 , overexpression of FoxO4 induced BCL6 ( Fig. 1d ). In Ph 1 ALL cells, FoxO factors are inactivated by PI3K/AKT 12 signalling, which is reversed by Pten ( Supplementary  Fig. 4 ). Deletion of Pten, hence, abrogated the ability of the leukaemia cells to upregulate BCL6 in response to TKI treatment ( Fig. 1e ).
In DLBCL, BCL6 is frequently translocated and suppresses p53mediated apoptosis 9, 16 . Although TKI treatment is less effective in p53 2/2 Ph 1 ALL 17 , recent studies showed that TKI paradoxically prevents the upregulation of p53 in response to DNA damage in Ph 1 ALL and chronic myelogenous leukaemia 18, 19 . A comparative gene expression analysis of BCL6 2/2 and BCL6 1/1 ALL cells (Supplementary Fig. 5 ) identified Cdkn2a (Arf), Cdkn1a (p21), p53 and p53bp1 as potential BCL6 target genes ( Supplementary Fig. 6 ). Arf and p53 protein levels were indeed unrestrained in BCL6 2/2 ALL ( Fig. 2a ). TKI treatment of BCL6 1/1 ALL resulted in strong upregulation of BCL6 with low levels of p53, whereas BCL6 2/2 ALL cells failed to curb p53 expression levels ( Supplementary Fig. 7 ). Likewise, TKI treatment increased excessively p53 levels when Pten-deficient ALL cells failed to upregulate BCL6 ( Fig. 1e ).
Identifying direct targets of BCL6 by chromatin immunoprecipitation (ChIP) in Ph 1 ALL ( Supplementary Figs 8-11 ), p53, p21 and p27 were among the genes with the strongest recruitment of BCL6 in TKItreated ALL ( Fig. 2b and Supplementary Figs 9-11). Given that cellcycle arrest and senescence-associated genes were among the BCL6 targets, we studied the cell-cycle profile of leukaemia cells. BCL6 2/2 ALL cells divided at a slightly reduced rate compared with BCL6 1/1 ALL cells ( Fig. 2c ). Treatment with adriamycin (0.05 mg ml 21 ) had no significant effect on BCL6 1/1 ALL cells in a senescence-associated b-galactosidase assay 20,21 but revealed that most BCL6 2/2 leukaemia cells were poised to undergo cellular senescence ( Fig. 2d ). These findings demonstrate that even low levels of BCL6 in the absence of TKI treatment are critical to downregulate Arf/p53. Clonal evolution of leukaemia involves acquisition of genetic lesions through DNA damage 22 . Interestingly, a comparative genomic hybridization analysis revealed that genetic lesions were less frequent in BCL6 deficient ALL ( Supplementary Fig. 12 ), suggesting that increased sensitivity to DNA damage limits clonal evolution in the absence of BCL6. Because Arf and p53 are critical negative regulators of self-renewal 23 , we performed colony-forming assays. The colony frequencies of BCL6 2/2 ALL cells were reduced by approximately 20-fold compared with BCL6 1/1 ALL (Fig. 3a ). To study self-renewal in vivo, we measured the ability of BCL6 1/1 and BCL6 2/2 ALL cells to initiate leukaemia in transplant recipients (Fig. 3b ). Using luciferase bioimaging, leukaemia engraftment was observed in both groups after 8 days. BCL6 1/1 ALL cells rapidly expanded and initiated fatal leukaemia, whereas BCL6 2/2 ALL cells failed to expand from the initial engraftment foci (Fig. 3c ). Some mice that received BCL6 2/2 ALL cells ultimately succumbed to leukaemia (Fig. 3b ). Flow cytometry, however, revealed that the leukaemias in the BCL6 2/2 group were in fact derived from endogenous CD45.1 1 cells of the irradiated recipients and not from the injected CD45.2 1 donor ALL cells (Supplementary Fig. 13 and asterisks in Fig. 3b ).
Defective leukaemia initiation may be a consequence of impaired homing to the bone marrow niche. Indeed, BCL6 2/2 ALL cells lack expression of CD44 ( Supplementary Fig. 14) , which is critical for homing of BCR-ABL1 LICs to the bone marrow microenvironment 24 . Retroviral reconstitution of CD44 markedly increased homing of BCL6 2/2 ALL cells to the bone marrow niche, but failed to rescue defective leukaemia initiation ( Supplementary Fig. 14) .
Using intrafemoral injection to circumvent homing defects, a limiting dilution experiment ( Fig. 3d ) showed that 5 million BCL6 2/2 ALL cells compared with only 10 3 BCL6 1/1 ALL cells were needed to initiate fatal leukaemia. These findings suggest that the frequency of LIC in BCL6 2/2 ALL (fewer than 1 in 100,000) is reduced by more than 100-fold compared with BCL6 1/1 ALL (at least 1 in 1,000). An alternative interpretation would be that LICs occur at a similar frequency in BCL6 2/2 ALL but with reduced self-renewal activity. To address potential 'exhaustion' of LICs, we performed a serial transplantation with ALL cells that gave rise to disease in primary recipients after injection of 5 million ALL cells. From the bone marrow, we isolated CD19 1 ALL cells for secondary intrafemoral injection. BCL6 2/2 leukaemia was not transplantable in secondary recipients ( Supplementary  Fig. 15 ). Although these findings do not exclude the possibility that the LIC frequencies are reduced in BCL6 2/2 ALL, they support the notion of LIC 'exhaustion' after secondary transplantation.
To explore the therapeutic usefulness of pharmacological inhibition of BCL6, we tested a BCL6 inhibitor (retro-inverso BCL6 peptideinhibitor (RI-BPI)), which blocks the repressor activity of BCL6 (ref. 25) . Gene expression analysis confirmed that RI-BPI is a selective and potent inhibitor of BCL6 ( Supplementary Fig. 16 ). We investigated the effect of RI-BPI on the self-renewal capacity of primary Ph 1 ALL and the initiation of leukaemia in a mouse xenograft model. Treatment with RI-BPI resulted in a reduction of colony formation and delayed progression of leukaemia. Likewise, treatment of Ph 1 ALL with RI-BPI induced cellular senescence ( Supplementary Fig. 17 ).
We next examined how gene dosage of BCL6 affects responses to TKI. For instance, Pten 2/2 ALL cells lack the ability to upregulate the p53-repressor BCL6 and are more sensitive to imatinib ( Fig. 1e and Supplementary Fig. 18 ). Dose-response studies in BCL6 1/1 , BCL6 1/2 and BCL6 2/2 ALL ( Fig. 4a ) showed that sensitivity to imatinib was significantly increased in BCL6 2/2 (half maximal effective concentration (EC 50 ) 0.17 mmol l 21 ) and even in BCL6 1/2 ALL cells (EC 50 0.67 mmol l 21 ) compared with BCL6 1/1 ALL cells (EC 50 1.10 mmol l 21 ; Fig. 4a ). These findings indicate that maximum levels of BCL6 expression are required to prevent TKI-induced cell death. Indeed, inducible activation of BCL6-ER T2 constructs 26 in BCL6 2/2 ALL cells conferred a strong survival advantage in the presence of imatinib ( Fig. 4b ). Activation of BCL6 in BCL6 1/1 ALL cells induced cell-cycle exit (not shown) and no additional survival advantage, because these cells already achieved maximal upregulation of endogenous BCL6 (Fig. 1a) .
To address the role of BCL6-mediated repression of p53 in TKIresistance, p53 2/2 and p53 1/1 ALL cells were treated with RI-BPI. The synergistic effect between TKI treatment and RI-BPI is indeed partly p53 dependent ( Supplementary Fig. 19 ). In p53 2/2 ALL cells, the effect of RI-BPI was significantly diminished compared with p53 1/1 ALL.
To confirm that BCL6 has a similar function in patient-derived Ph 1 ALL, primary ALL cells were transduced with a dominant-negative BCL6 mutant (DN-BCL6-ER T2 ) 26 , which resulted in a marked competitive disadvantage of Ph 1 ALL cells, that was further enhanced by imatinib treatment (Fig. 4c ). Similar observations in mouse ALL and in an established Ph 1 ALL cell line demonstrated that BCL6 promotes survival of TKI-treated Ph 1 ALL ( Supplementary Fig. 20) .
To test the effect of BCL6 inhibition on TKI resistance, we cultured four primary Ph 1 ALL in the presence or absence of imatinib, RI-BPI or a combination of both ( Supplementary Fig. 21 ). Initially, all four Ph 1 ALL cases responded to imatinib treatment, but subsequently rebounded and were no longer sensitive to imatinib (10 mmol l 21 ). RI-BPI alone showed only slight effects, whereas the combination of RI-BPI and imatinib rapidly induced cell death and effectively prevented a rebound in all four cases ( Supplementary Fig. 21 ). These ALL cells were treated with and without imatinib (10 mmol l 21 ) for 24 h. Upregulation of BCL6 was compared with expression levels in DLBCL by western blot. b, BCR-ABL1-transformed mouse ALL cells were transduced with a constitutively active Stat5 mutant (STAT5 CA ) or a control vector (green fluorescent protein, GFP) and treated either with or without imatinib. BCL6 western blot was performed using b-actin as loading control. c, BCL6 expression upon imatinib treatment was studied by western blot in the presence or absence of Cre-mediated deletion of Stat5 in BCR-ABL1-transformed Stat5 fl/fl mouse ALL. d, Mouse BCR-ABL1 ALL cells were transduced with FoxO4-puromycin or a puromycin control vector and subjected to antibiotic selection. Cells were collected and BCL6 mRNA levels were measured by qRT-PCR relative to Hprt. e, Imatinib-induced BCL6 expression was studied by western blot in the presence or absence of Cre-mediated deletion of Pten in BCR-ABL1-transformed Pten fl/fl mouse ALL cells.
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findings suggest that prolonged treatment with a combination of imatinib/RI-BPI prevents acquisition of TKI-resistance. We next examined the effect of imatinib/RI-BPI combinations on primary TKI-resistance in Ph 1 ALL. To this end, four human Ph 1 ALL cell lines that lacked BCR-ABL1 kinase mutations ( Supplementary Table 1) but which were highly refractory to imatinib (10 mmol 1 2l ) were treated with or without imatinib, RI-BPI or a combination of both. Imatinib alone did not achieve a therapeutic response, whereas the combination with RI-BPI potentiated the effect of imatinib on the refractory ALL cells ( Supplementary Fig. 22 ). a, Ten thousand BCL6 2/2 or BCL6 1/1 BCR-ABL1 ALL cells were plated in semisolid agar, and colonies were counted after 10 days (numbers denote means 6 SD, n 5 3). b, Overall survival of mice injected with 100,000 BCL6 2/2 and BCL6 1/1 BCR-ABL1 ALL cells was compared by Kaplan-Meier analysis.
Mice that developed CD45.1 1 endogenous leukaemia instead of leukaemia from injected CD45.2 1 cells are indicated by asterisks (see Supplementary   Fig. 13 ). c, For an SCID LIC (SL-IC) experiment, BCL6 2/2 and BCL6 1/1 BCR-ABL1 ALL cells were labelled with firefly luciferase and intravenously injected into sublethally irradiated NOD/SCID mice. d, The SL-IC assay was repeated as a limiting dilution experiment (10 3 , 10 4 , 10 5 , 5 million cells) and leukaemia cells were directly injected into the femoral bone marrow to circumvent potential engraftment defects. 
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To study the efficacy of combined tyrosine kinase and BCL6 inhibition in vivo, primary Ph 1 ALL cells were labelled with luciferase and xenografted into mice. Recipient mice were treated with either vehicle, nilotinib or a combination of nilotinib and RI-BPI. Nilotinib is more potent than imatinib, which only has marginal effects in mice 27, 28 . Bioimaging demonstrated that seven to ten injections of RI-BPI significantly enhanced the effect of nilotinib (Fig. 4d, e and Supplementary Fig. 23 ). Whereas all mice treated with nilotinib alone succumbed to leukaemia within 99 days after injection, seven of eight mice treated with RI-BPI/nilotinib combination were still alive after 140 days (Fig. 4d, e) . Also, in a model for full-blown mouse leukaemia, TKI/ RI-BPI combinations proved effective and significantly prolonged survival ( Supplementary Fig. 24 ). Establishing a potential therapeutic window of nilotinib/RI-BPI combinations, we found no evidence of relevant toxicity ( Supplementary Figs 25 and 26 and Supplementary  Table 2 ).
Although transcription factors have been considered intractable therapeutic targets, the recent development of a small molecule inhibitor against BCL6 (ref. 29 ) holds promise for effectively targeting TKIresistance in patients with Ph 1 ALL. Because TKI-resistance develops in virtually all cases of Ph 1 ALL, it appears particularly important to target this novel pathway of TKI-resistance. Table 1 ) were cultured on OP9 stroma cells in alpha minimum essential medium without ribonucleotides and deoxyribonucleotides, supplemented with 20% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 IU ml 21 penicillin and 100 mg ml 21 streptomycin. Human ALL cell lines were maintained in RPMI with GlutaMAX containing 20% FBS, 100 IU ml 21 penicillin and 100 mg ml 21 streptomycin. Mouse BCR-ABL1transformed ALL cells were maintained in IMDM with GlutaMAX containing 20% FBS, 100 IU ml 21 penicillin, 100 mg ml 21 streptomycin and 50 mM 2-mercaptoethanol. Cell cultures were kept at 37 uC in a humidified incubator under a 5% CO 2 atmosphere. BCR-ABL1 transformation. Transfection of a murine stem cell virus (MSCV)based retroviral vector encoding BCR-ABL1 was performed using Lipofectamine 2000. Retroviral supernatant was produced by co-transfecting 293FT cells with the plasmids pHIT60 and pHIT123. Virus supernatant was collected, filtered through a 0.45 mm filter and loaded by centrifugation (2,000g, 90 min at 32 uC) on 50 mg ml 21 RetroNectin-coated non-tissue well plates. Extracted bone marrow cells from mice were transduced by BCR-ABL1 in the presence of 10 ng ml 21 recombinant murine interleukin-7 in RetroNectin-coated Petri dishes. a, Imatinib sensitivity of BCL6 2/2 , BCL6 1/2 and BCL6 1/1 ALL cells was measured in a resazurin viability assay. b, BCL6 2/2 ALL cells were transduced with BCL6-ER T2 or ER T2 vectors (tagged with GFP). ALL cells were treated with or without 1 mmol l 21 imatinib, and BCL6-ER T2 or ER T2 were induced by 4-hydroxytamoxifen. Relative changes of GFP 1 cells after induction are indicated. c, Patient-derived Ph 1 ALL cells (ICN1) were transduced with inducible dominant-negative BCL6 (DN-BCL6-ER T2 ) or ER T2 control vectors. ALL cells were treated with or without 10 mmol l 21 imatinib and DN-BCL6-ER T2 or ER T2 were induced by 4-hydroxytamoxifen. Relative changes of GFP 1 cells after induction are indicated. d, Patient-derived Ph 1 ALL cells (TXL2) were labelled with luciferase and 100,000 cells were injected. Mice were treated seven times with either vehicle (green), nilotinib (25 mg kg 21 ; grey) or a combination of nilotinib and RI-BPI (25 mg kg 21 ; red). Treated mice are shown in e, a Kaplan-Meier survival analysis. Treatment days are indicated by arrowheads. . Leukaemia cells from bone marrow biopsy of patients with Ph 1 ALL were xenografted into sublethally irradiated NOD/SCID mice by tail vein injection. After passaging, leukaemia cells were collected and cultured on OP9 stroma cells in alpha minimum essential medium (Alpha-MEM, Invitrogen) without ribonucleotides and deoxyribonucleotides, supplemented with 20% fetal bovine serum, 2 mmol l 21 L-glutamine, 1 mmol l 21 sodium pyruvate, 100 IU ml 21 penicillin and 100 mg ml 21 streptomycin. The human ALL cell lines BV173, NALM-1, SUP-B15 and TOM1 (obtained from Deutsche Sammlung von Microorganismen und Zellkulturen (DSMZ)) were maintained in Roswell Park Memorial Institute medium (RPMI-1640, Invitrogen) with GlutaMAX containing 20% fetal bovine serum, 100 IU ml 21 penicillin and 100 mg ml 21 streptomycin. Retroviral constructs and transduction. Transfection of retroviral constructs encoding BCR-ABL1-IRES-GFP 30 , BCR-ABL1-IRES-Neo, STAT5-CA 31 , CD44S-Puro 32 , FoxO4-Puro, BCL6-ER T2 -GFP 26 , ER T2 -GFP, DN-BCL6-ER T2 -GFP, Cre-ER T2 -Puro 33 , Cre-IRES-GFP, Puro-, Neo-and GFP-empty vector controls were performed using Lipofectamine 2000 (Invitrogen) with Opti-MEM media (Invitrogen). Retroviral supernatant was produced by co-transfecting HEK 293FT cells with the plasmids pHIT60 (ref. 34) (gag-pol) and pHIT123 (ecotropic env) or pHIT456 (amphotropic env). 293FT cells were cultured in high glucose Dulbecco's modified Eagle's medium (DMEM, Invitrogen) with GlutaMAX containing 10% fetal bovine serum, 100 IU ml 21 penicillin, 100 mg ml 21 streptomycin, 25 mmol l 21 HEPES, 1 mmol l 21 sodium pyruvate and 0.1 mmol l 21 non-essential amino acids. Regular media were replaced after 16 h by growth media containing 10 mmol l 21 sodium butyrate. After incubation for 8 h, the media were changed back to regular growth media. Twenty-four hours later, the virus supernatant was collected, filtered through a 0.45 mm filter and loaded by centrifugation (2,000g, 90 min at 32 uC) two times on 50 mg ml 21 RetroNectin-(Takara) coated non-tissue six-well plates. Two million to three million cells were transduced per well by centrifugation at 500g for 30 min and maintained for 48 h at 37 uC with 5% CO 2 before transferring into culture flasks. Transduced cells with oestrogen receptor fusion proteins were induced with 4-hydroxytamoxifen (500 nM).
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In vivo model for BCR-ABL1-transformed ALL and bioluminescence imaging. After cytokine-independent proliferation, BCR-ABL1-transformed ALL cells were labelled with a lentiviral vector encoding firefly luciferase with a neomycin selection marker. After selection with 0.5-2 mg ml 21 G418 for 10 days, luciferase-labelled ALL cells were injected into sublethally irradiated (250 cGy) NOD/SCID mice. Human primary leukaemia cells were transduced with a lentiviral firefly luciferase carrying a GFP marker. After expansion of sorted GFP 1 cells, 1 3 10 5 cells were injected through the tail vein into sublethally irradiated NOD/SCID mice. Bioimaging of leukaemia progression in mice was performed at different time points using an in vivo IVIS 100 bioluminescence/optical imaging system (Xenogen). D-Luciferin (Promega) dissolved in PBS was injected intraperitoneally at a dose of 2.5 mg per mouse 15 min before measuring the luminescence signal. General anaesthesia was induced with 5% isoflurane and continued during the procedure with 2% isoflurane introduced through a nose cone. All mouse experiments were subject to institutional approval by the Children's Hospital Los Angeles Institutional Animal Care and Use Committee. Extraction of bone marrow cells from mice. To avoid inflammation-related effects in BCL6 2/2 mice 35 , bone marrow cells were extracted from young agematched BCL6 1/1 and BCL6 2/2 mice (younger than 6 weeks of age) without signs of inflammation. Bone marrow cells were obtained by flushing cavities of femur and tibia with PBS. After filtration through a 70 mm filter and depletion of erythrocytes using a lysis buffer (BD PharmLyse, BD Biosciences), washed cells were either frozen for storage or subjected to further experiments. BCL6 2/2 , Stat5 fl/fl , Pten fl/fl and p53 2/2 mice. A summary of mouse strains used in this study is provided in Supplementary Table 3 . Bone marrow cells from BCL6 2/2 (generated in R. Dalla-Favera's laboratory) 36 , Stat5 fl/fl (generated in L. Henninghausen's laboratory) 37 , Pten fl/fl (generated in H. Wu's laboratory) 38 and p53 2/2 (obtained from Jackson Laboratory) mice were collected and retrovirally transformed by BCR-ABL1 (ref. 30) in the presence of 10 ng interleukin-7 per milliliter (Peprotech) in RetroNectin-(Takara) coated Petri dishes as described below. All BCR-ABL1-transformed ALL cells derived from bone marrow of mice were maintained in Iscove's modified Dulbecco's medium (IMDM, Invitrogen) with GlutaMAX containing 20% fetal bovine serum, 100 IU ml 21 penicillin, 100 mg ml 21 streptomycin and 50 mM 2-mercaptoethanol. BCR-ABL1-transformed ALL cells were propagated only for short periods of time and usually not longer than for 2 months to avoid acquisition of additional genetic lesions during long-term cell culture. RI-BPI. Homo-dimerization of the amino (N)-terminal Broad Complex, Tramtrack, Bric à brac (BTB) domain of BCL6 forms a lateral groove motif, which is required to recruit co-repressor proteins such as BCL6 co-repressor (BCoR), nuclear receptor co-repressor (N-CoR) and silencing mediator of retinoid and thyroid receptors (SMRT). BCoR, NCoR and SMRT interact in a mutually exclusive manner with an 18-amino-acid motif in the lateral groove of the BCL6 BTB domain to form a BCL6 repression complex 39, 40 . A recombinant peptide containing the SMRT BBD (BCL6-binding domain) along with a cell-penetrating TAT domain was able to inhibit the transcriptional repressor activity of BCL6 41 . Based on this initial work, the peptidomimetic molecule RI-BPI with superior potency and stability was developed 25 and used for BCL6-inhibition. RI-BPI represents a retro-inverso TAT-BBD-Fu (fusogenic) peptide 25 that was synthesized by Biosynthesis Inc. (Lewisville, TX) and stored lyophilized at 220 uC until reconstituted with sterile, distilled, degassed water immediately before use. The purity determined by high-performance liquid chromatography-mass spectrometry was 95% or higher. RI-BPI was injected intraperitoneally into mice. BCR-ABL1 TKI. Imatinib (STI571) and nilotinib (AMN107) were obtained from Novartis Pharmaceuticals or from LC Laboratories. Stock solutions of imatinib were prepared in sterile, distilled water at 10 mmol l 21 and stored at 220 uC. Nilotinib was either dissolved in DMSO (dimethyl sulphoxide) or NMP (N-Methyl-2-pyrrolidone) just before administration. Nilotinib dissolved in DMSO was vortexed with four volumes of peanut butter until a homogeneous mixture was formed. Nilotinib (free base) solubilized in NMP was diluted with PEG 300 (polyethylene glycol 300) in a 10/90 (vol/vol) ratio. Cohorts of mice were treated with oral administration of vehicle or nilotinib (25 mg kg 21 day 21 or 50 mg kg 21 day 21 ) once daily at indicated time points. Clonality analysis and spectratyping of B-cell populations. Immunoglobulin V H -DJ H gene rearrangements were amplified using PCR primers specific for the J558 V H region gene with a primer specific for the Cm constant region gene. Using a FAM-conjugated Cm constant region or a J H gene-specific primer in a run-off reaction, PCR products were labelled and subsequently analysed on a capillary sequencer (ABI3100, Applied Biosystems) by fragment-length analysis. Sequences of primers used are given in Supplementary Table 4 . Affymetrix GeneChip analysis. Total RNA from cells used for microarray or RT-PCR analysis was isolated by RNeasy (Qiagen) purification. RNA quality was first checked by using an Agilent Bioanalyser (Agilent Technologies). Complementary DNA (cDNA) was generated from 5 mg of total RNA using a poly(dT) oligonucleotide containing a T7 RNA polymerase initiation site and the SuperScript III Reverse Transcriptase (Invitrogen). Biotinylated cRNA was generated and fragmented according to the Affymetrix protocol and hybridized to U133A 2.0 human or 430 mouse microarrays (Affymetrix). After scanning (GeneChip Scanner 3000 7G, Affymetrix) of the GeneChip arrays, the generated CEL files were imported to BRB Array Tool (http://linus.nci.nih.gov/BRB-ArrayTools.html) and processed using the RMA algorithm (Robust Multi-array Average) for normalization and summarization. Relative signal intensities of probe sets were determined by comparing the signal intensity from TKI-treated and untreated cells to the average signal value of the respective cell line or a group of cell lines. The calculated signal ratios of probe sets were visualized as a heatmap with Java Treeview. Target validation of RI-BPI in human Ph 1 ALL cells. Ph 1 ALL cell lines (BV173, NALM1 and TOM1) were treated with vehicle (control), 10 mmol l 21 imatinib or imatinib 1 20 mmol l 21 RI-BPI for 24 h and maintained in Allprotect (Qiagen) at 280 uC until RNA isolation using an RNeasy Plus kit (Qiagen). RNA integrity was determined using the RNA 6000 Nano LabChip kit on Agilent 2100 Bioanalyser (Agilent Technologies). Two independent samples were analysed for each condition. RNA (1 mg) was hybridized to Agilent 60-mer Whole Human Genome Microarrays (part number G4112A) according to the manufacturer's recommendations. After hybridization, the processed microarrays were scanned with the Agilent DNA microarray scanner (part number G2505C) and extracted with Agilent Feature Extraction software version 8.5 (GE1-v5_10_Apr08). For computational analysis of signal, we used the dye-normalized signal after surrogate algorithm (gProcessedSignal) extracted from the .txt files and process for each array and for all the probes. This value was subjected to log 2 transformation and median array normalization. The fold changes of imatinib compared with control and (imatinib 1 RI-BPI) compared with imatinib were calculated for each cell line and for each gene. A data set containing previously identified BCL6 target genes (obtained from Nimblegen arrays) was mapped into the Agilent probe sets using the Agilent and NimbleGen array annotation files. To determine if two data sets differed significantly, we compared the fold change in BCL6 target genes with the fold change in BCL6 non-target genes for each data set (imatinib compared with control, and imatinib 1 RI-BPI compared with imatinib) by the Kolmogorov-Smirnov test 42 . The Kolmogorov-Smirnov test deter-LETTER RESEARCH
